



FRANCE

Pharmacoepidemiology Unit, Lyon 1 University, Eric Van Ganse

Pricing

- Price policies for pharmaceuticals
Statutory pricing for reimbursable pharmaceuticals at ex-factory price level
External price referencing (DE, ES, IT, UK) for innovative pharmaceuticals, internal price referencing for other reimbursable pharmaceuticals
- Wholesale Mark-ups
Regressive mark-up scheme for reimbursable pharmaceuticals
- Pharmacy Mark-ups
Regressive mark-up scheme for reimbursable pharmaceuticals
- VAT
2.1% on reimbursable pharmaceuticals, 5.5% on non-reimbursable pharmaceuticals (vs 19.6% standard VAT)

Reimbursement

- Positive / negative list
70% of all pharmaceuticals on the market included in the positive list
- Reference Price System
Since August 2003 for generic groups (ATC 5 level)
- Co-payment
35%, 65% and 85% depending on the product
- Mechanisms for vulnerable groups
100% reimbursement for patients with long-term diseases (30 diseases) and low income (< 7,083 €/year)
- Reforms
August 2003 : implementation of reference price system
- August 2004: Health insurance reform
- March 2006 : de-listing of 152 pharmaceuticals